HuGE Literature Finder
Records
1
-
4
Impact of somatic and germline mutations on the outcome of systemic mastocytosis. Blood advances 2018 11 2 (21): 2814-2828. Muñoz-González Javier I, Jara-Acevedo María, Alvarez-Twose Iván, Merker Jason D, Teodosio Cristina, Hou Yanli, Henriques Ana, Roskin Krishna M, Sanchez-Muñoz Laura, Tsai Albert G, Caldas Carolina, Matito Almudena, Sánchez-Gallego J Ignacio, Mayado Andrea, Dasilva-Freire Noelia, Gotlib Jason R, Escribano Luis, Orfao Alberto, García-Montero Andrés |
A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. British journal of haematology 2015 Apr 169 (1): 71-6. Wassie Emnet, Finke Christy, Gangat Naseema, Lasho Terra L, Pardanani Animesh, Hanson Curtis A, Ketterling Rhett P, Tefferi Ayal |
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014 Apr 123 (14): 2157-60. Guglielmelli Paola, Biamonte Flavia, Rotunno Giada, Artusi Valentina, Artuso Lucia, Bernardis Isabella, Tenedini Elena, Pieri Lisa, Paoli Chiara, Mannarelli Carmela, Fjerza Rajmonda, Rumi Elisa, Stalbovskaya Viktoriya, Squires Matthew, Cazzola Mario, Manfredini Rossella, Harrison Claire, Tagliafico Enrico, Vannucchi Alessandro M, , |
Clinical effect of point mutations in myelodysplastic syndromes. The New England journal of medicine 2011 Jun 364 (26): 2496-506. Bejar Rafael, Stevenson Kristen, Abdel-Wahab Omar, Galili Naomi, Nilsson Björn, Garcia-Manero Guillermo, Kantarjian Hagop, Raza Azra, Levine Ross L, Neuberg Donna, Ebert Benjamin |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 22, 2022
- Content source: